List of ACE inhibitors: Trade and Generic Names



Coming up next is a rundown of brand and regular names of ACE inhibitors. These medications with the pertinent nonexclusive names are accessible locally and are utilized for (hypertension).

The rundown is arranged by the expense every day of utilizing the particular ACE inhibitor. The pieces of the table are as per the following:

Sentinel rating is the medication rating (between 0-100) consistently corresponding to the medications accessible for hypertension. The lower the number, the lower the expense every day.

Brand is the brand name of the medication.

Regular name is the name of the dynamic fixing. Ines with the equivalent hereditary name have comparative pharmacological impacts.

The dose is the measure of medication in a tablet.

Start-up class alludes to the occasions every day the medication is first recommended.

The unit cost is the producer's cost per tablet.

The expense every day is the complete expense of taking the medication day by day, considering the portion and the beginning recurrence.



How is this data used?
The data can be used by physicians to compare the costs of different ACE inhibitors. Provides physicians with a quick survey of the comparative cost and cost per day of using a particular drug.

Patients can use the data to find more affordable ACE inhibitors that have a biologic utility similar to their current prescription.


Centile Rank
Brand Name
Generic Name
Stock Dose (mg)
Initial Freq.
Unit Price
Cost per day
11
Pharex
Enalapril
5
1
8.00
8.00
20
Hypace
Enalapril
5
1
10.82
10.82
27
Tensoril
Captopril
25
2
6.08
12.15
33
Naprilate
Enalapril
5
1
13.50
13.50
37
Ramipro
Ramipril
2.5
1
14.30
14.30
41
Coversyl
Perindopril
5
1
30.17
15.08
47
Hartylox
Captopril
25
2
8.43
16.86
48
Bloc-Med
Captopril
25
2
8.60
17.20
64
Norten
Imidapril
5
1
22.23
22.23
65
Vascor
Imidapril
5
1
22.23
22.23
70
Renitec
Enalapril
5
1
23.69
23.69
81
Ritemed
Captopril
25
2
16.51
33.02
90
Tritace
Ramipril
2.5
1
43.17
43.17
91
Accupril
Quinapril
10
1
44.72
44.72

Post a Comment

0 Comments